Newswise — Researchers from the Hackensack Merdian Health John Theurer Cancer Center at Hackensack University Medical Center will present results from 46 cancer-related studies during the American Society of Hematology (ASH) 59th Annual Meeting, which will take place December 9 – 12, 2017 in Atlanta. The studies examine new cancer treatments, ways to predict the best treatment outcomes, and patient quality of life issues.
“ASH is a great venue for sharing best practices and learning about the latest treatment approaches – we are proud to help contribute by presenting our recent scientific work,” André Goy, MD, MS, chairman and director, division chief of Lymphoma, John Theurer Cancer Center; chief science officer and director of Research and Innovation, RCCA; professor of medicine, Georgetown University. “Our researchers will keep working to improve oncology and help develop some of the newest approaches to treating cancer. This will remain a priority for our cancer center.”
Among other promising research, John Theurer Cancer Center investigators will present highlights from studies in mantle cell lymphoma (MCL), stem cell transplantation, CAR T-cell therapy, precision medicine in multiple myeloma (MM), Hodgkin lymphoma and new combinations in blood cancers at the ASH annual meeting.
Novel strategies in Mantle Cell Lymphoma
- 155 - Efficacy and Safety of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in the Phase 2 ACE-LY-004 Study, Andre Goy, MD et al.. Oral Presentation - Saturday, December 9, 2017: 1:00 PM, Bldg A, Lvl 4, A411-A412 (Georgia World Congress Center)
- 151 - Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis, Andre Goy, MD et al..Oral Presentation - Saturday, December 9, 2017: 12:00 PM, Bldg A, Lvl 4, A411-A412 (Georgia World Congress Center)
- 2785 - Phase Ib-II Study of Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib, w/ Lenalidomide and Rituximab in Relapsed / Refractory Mantle Cell Lymphoma, Andre Goy, MD et al.. Poster Presentation- Sunday, December 10, 2017, 6:00 PM-8:00 PM, Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)
Novel strategies in stem cell transplantation
- 340 - Preliminary Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (I) and Nivolumab (N) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematologic Malignancies – Alan Skarbnik, MD, et al.. Oral Presentation CPIT-001 Trial Sunday, December 10, 2017: 8:15 AM, Bldg B, Lvl 4, B401-B402 (Georgia World Congress Center)
- 1862 - Early Regulatory and Memory T Cell Profiles Post-ASCT in the Presence of Checkpoint Inhibitor (Nivolimumab+Ipilimumab) Double Therapy in Patients with High-Risk Multiple Myeloma, Poster Presentation, Saturday, December 9, 2017, 5:30 PM-7:30 PM, Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)
CAR T cells therapy
- 740 - Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy, Oral Presentation, Monday, December 11, 2017: 3:00 PM, Bldg C, Lvl 1, Hall C1 (Georgia World Congress Center)
Precision medicine in Multiple Myeloma
- 679 - Incidence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients with Multiple Myeloma, Alan Richter, MD et al.., Oral Presentation, Monday, December 11, 2017: 10:30 AM, Bldg C, Lvl 2, C208-C210 (Georgia World Congress Center)
- 395 - Utility of Clinical-Grade Sequencing of Relapsed Multiple Myeloma Patients; Interim Analysis of the Multiple Myeloma Research Foundation (MMRF) Molecular Profiling Protocol, Oral Presentation, Sunday, December 10, 2017: 10:30 AM Bldg B, Lvl 3, B304-B305 (Georgia World Congress Center)
- 1831 - A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone As Post Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma, Noa Biran, MD et al.., Poster Presentation, Saturday, December 9, 2017, 5:30 PM-7:30 PM, Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)
Novel therapies and new combinations in Hodgkin Lymphoma
- 6 - Brentuximab Vedotin Plus Doxorubicin, Vinblastine, Dacarbazine (A+AVD) As Frontline Therapy Demonstrates Superior Modified Progression-Free Survival Versus ABVD in Patients with Previously Untreated Stage III or IV Hodgkin Lymphoma (HL): The Phase 3 Echelon-1 Study, Plenary Scientific Session, Sunday, December 10, 2017, 2:00 PM-4:00 PM, Bldg C, Lvl 1, Hall C2-C3 (Georgia World Congress Center)
- 649 - Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma, Oral Presentation, Monday, December 11, 2017: 10:30 AM, Bldg A, Lvl 4, Marcus Aud. (Georgia World Congress Center)
- 651 - Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study, Oral Presentation, Monday, December 11, 2017: 11:00 AM, Bldg A, Lvl 4, Marcus Aud. (Georgia World Congress Center)
Other novel therapies and new combinations in blood cancers
- 410 - Results from a Phase 1/2 Study of INCB050465, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies (CITADEL-101), Oral Presentation, Sunday, December 10, 2017: 12:15 PM, Bldg C, Lvl 1, Hall C1 (Georgia World Congress Center)
- 891 - Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles, Oral Presentation, Monday, December 11, 2017: 6:45 PM, Bldg B, Lvl 5, Murphy BR 1-2 (Georgia World Congress Center)
“Our research presented at this conference would not have been possible without the patients who participate in our clinical trials,” said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., chief innovation officer, professor and vice president of cancer services, John Theurer Cancer Center. “We are thankful to our patients, our researchers, and our partnering institutions who help us bring novel therapies and improved regimens for cancer patients.”
For more information about the ASH conference or the research being presented, go to www.hematology.org/Annual-Meeting/.
ABOUT HACKENSACK MERIDIAN HEALTH Hackensack Meridian Health is a leading not-for-profit health care organization that is the most comprehensive and truly integrated health care network in New Jersey, offering a complete range of medical services, innovative research and life-enhancing care. Hackensack Meridian Health comprises 13 hospitals, including two academic medical centers, two children's hospitals and nine community hospitals, physician practices, more than 120 ambulatory care centers, surgery centers, home health services, long-term care and assisted living communities, ambulance services, lifesaving air medical transportation, fitness and wellness centers, rehabilitation centers, and urgent care and after-hours centers. Hackensack Meridian Health has 28,000 team members, more than 6,000 physicians and is a distinguished leader in health care philanthropy, committed to the health and well-being of the communities it serves.
The Network's notable distinctions include having one of only five major academic medical centers in the nation to receive Healthgrades America's 50 Best Hospitals Award for five or more consecutive years, the number one hospital in New Jersey as ranked by U.S. News and World Report, consistently achieving Magnet® recognition for nursing excellence from the American Nurses Credentialing Center, recipient of the John M. Eisenberg Award for Patient Safety and Quality from The Joint Commission and the National Quality Forum, a six-time recipient of Fortune's "100 Best Companies to Work For," one of the "20 Best Workplaces in Health Care" in the nation, and the number one "Best Place to Work for Women." Hackensack Meridian Health is a member of AllSpire Health Partners, an interstate consortium of leading health systems, to focus on the sharing of best practices in clinical care and achieving efficiencies.
The hospitals of Hackensack Meridian Health include: academic medical centers – Hackensack University Medical Center in Hackensack, Jersey Shore University Medical Center in Neptune; children's hospitals – Joseph M. Sanzari Children's Hospital in Hackensack, K. Hovnanian Children's Hospital in Neptune; community hospitals – Ocean Medical Center in Brick, Riverview Medical Center in Red Bank, Mountainside Medical Center in Montclair, Palisades Medical Center in North Bergen, Raritan Bay Medical Center in Perth Amboy, Southern Ocean Medical Center in Manahawkin, Bayshore Medical Center in Holmdel, Raritan Bay Medical Center in Old Bridge, and Pascack Valley Medical Center in Westwood. For additional information, please visit www.HackensackMeridianHealth.org.
ABOUT JOHN THEURER CANCER CENTER AT HACKENSACK UNIVERSITY MEDICAL CENTER
John Theurer Cancer Center at Hackensack University Medical Center is New Jersey’s largest and most comprehensive center dedicated to the diagnosis, treatment, management, research, screenings, and preventive care as well as survivorship of patients with all types of cancers. The 14 specialized divisions covering the complete spectrum of cancer care have developed a close-knit team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. Each year, more people in the New Jersey/New York metropolitan area turn to John Theurer Cancer Center for cancer care than to any other facility in New Jersey. Housed within a 775-bed not-for-profit teaching, tertiary care, and research hospital, John Theurer Cancer Center provides state-of-the-art technological advances, compassionate care, research innovations, medical expertise, and a full range of aftercare services that distinguish John Theurer Cancer Center from other facilities. For additional information, please visit www.jtcancercenter.org.
Hackensack Meridian Health
John Theurer Cancer Center
60 2nd Street
Hackensack, NJ 07601
O: 551-996-3764 C: 201-956-7191